Kuala Lumpur, March 28 -- The Malaysian government will intensify support for domestic drug production to reduce healthcare costs and improve access to medicines for its citizens.
A report by BMI, a market research firm under Fitch Solutions, indicates that the focus of this policy is to increase the share of domestically produced medical products and establish a legal framework that prioritises essential medicines, especially generic drugs and biosimilars.
The Malaysian Ministry of Health will introduce a significant shift in its procurement policy, prioritising suppliers with investments in local production, while also strengthening its capacity to negotiate prices and making affordable generic drugs the default prescription option when...